Parabilis Medicines, Inc. (PBLS)
| Market Cap | 3.85B |
| Revenue (ttm) | 148,000 |
| Net Income | -231.67M |
| EPS | -23.45 |
| Shares Out | 123.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,119,022 |
| Open | 32.32 |
| Previous Close | 32.47 |
| Day's Range | 29.57 - 32.32 |
| 52-Week Range | 24.51 - 42.49 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 41.75 (+33.81%) |
| Earnings Date | Aug 13, 2026 |
About PBLS
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-ca... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PBLS stock is "Strong Buy." The 12-month stock price target is $41.75, which is an increase of 33.81% from the latest price.
News
Parabilis Medicines falls -12.5%
Parabilis Medicines (PBLS) is down -12.5%, or -$5.22 to $36.51.
Parabilis Medicines Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The Helicon platform enables targeting of undruggable proteins, with Zolucatetide showing strong efficacy and safety in desmoid tumors and promising early results in FAP and ACP. Phase III trials, pipeline expansion, and a Regeneron partnership are underway, supported by $1.1B in cash.
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with seri...
Parabilis Medicines appoints Craig Tendler to board of directors
Parabilis Medicines (PBLS) announced the appointment of Craig Tendler to its board of directors. Tendler has served as a scientific advisor to Parabilis Medicines, a role he will continue alongside…
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.
CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serio...
Parabilis Medicines reports Q2 EPS ($2.32), consensus (24c)
Reports Q2 revenue $148,000, consensus $16.67M. “This quarter marked meaningful progress toward our long-term vision as we continued advancing zolucatetide across multiple Wnt/beta-catenin-driven dise...
Parabilis Medicines Slides: Corporate presentation
Parabilis Medicines has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors
Parabilis Medicines Earnings release: Q2 2026
Parabilis Medicines released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Parabilis Medicines Quarterly report: Q2 2026
Parabilis Medicines has published its Q2 2026 quarterly earnings report on August 13, 2026.
Parabilis Medicines initiated with an Outperform at Leerink
Leerink initiated coverage of Parabilis Medicines (PBLS) with an Outperform rating and $40 price target The firm believes the company’s lead asset zolucatetide has the potential to be active across…
Parabilis Medicines initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of Parabilis Medicines (PBLS) with an Outperform rating and no price target Parabilis is “taking bold strides in drug development,” initial findings in desmoid tumors a...
Parabilis Medicines initiated with a Buy at BofA
BofA initiated coverage of Parabilis Medicines (PBLS) with a Buy rating and $45 price target Parabilis is advancing AI-enabled therapeutics for previously undruggable targets, with lead candidate zolu...
Parabilis Medicines initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Parabilis Medicines (PBLS) with a Buy rating and $40 price target The “Helicon platform” serves as a differentiated product engine and lead product candidate zolucatet...
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines address...
Parabilis Medicines off highs, but still up over 50% from IPO price
The shares in afternoon trading are up $10.67 from the $20.00 offer price to $30.67.
Parabilis Medicines opens at $33.35, IPO priced at $20.00
Parabilis Medicines (PBLS) priced 33.5M shares at $20.00. The deal size was increased to 33.5M shares and priced above the $17.00-$19.00 target range. Leerink, BofA, Evercore ISI, Guggenheim and LifeS...
Parabilis Medicines 33.5M share IPO priced at $20.00
The deal size was increased to 33.5M shares and priced above the $17.00-$19.00 target range. Leerink, BofA, Evercore ISI, Guggenheim and LifeSci Capital are acting as joint book running managers…
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines address...
Parabilis Medicines aims to raise $633 million in upsized US IPO
Biopharmaceutical company Parabilis Medicines said on Tuesday it was aiming to raise as much as $633.3 million in its upsized initial public offering in the U.S.
Parabilis Medicines aims to raise up to $475 million in US IPO
Biopharmaceutical company Parabilis Medicines said on Thursday it is aiming to raise as much as $475 million in its U.S. initial public offering.
Biopharmaceutical firm Parabilis Medicines files for US IPO
Biopharmaceutical company Parabilis Medicines has filed for an initial public offering in the United States, according to a regulatory filing on Tuesday.
Parabilis Medicines IPO Registration Document (S-1)
Parabilis Medicines has filed to go public with an IPO on the NASDAQ